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ABSTRACT
Objective: There is a widely held assumption that
engagement by clinicians and healthcare organisations
in research improves healthcare performance at various
levels, but little direct empirical evidence has
previously been collated. The objective of this study
was to address the question: Does research
engagement (by clinicians and organisations) improve
healthcare performance?
Methods: An hourglass-shaped review was
developed, consisting of three stages: (1) a planning
and mapping stage; (2) a focused review concentrating
on the core question of whether or not research
engagement improves healthcare performance; and (3)
a wider (but less systematic) review of papers
identified during the two earlier stages, focusing on
mechanisms.
Results: Of the 33 papers included in the focused
review, 28 identified improvements in health services
performance. Seven out of these papers reported some
improvement in health outcomes, with others reporting
improved processes of care. The wider review
demonstrated that mechanisms such as collaborative
and action research can encourage some progress
along the pathway from research engagement towards
improved healthcare performance. Organisations that
have deliberately integrated the research function into
organisational structures demonstrate how research
engagement can, among other factors, contribute to
improved healthcare performance.
Conclusions: Current evidence suggests that there is
an association between the engagement of individuals
and healthcare organisations in research and
improvements in healthcare performance. The
mechanisms through which research engagement
might improve healthcare performance overlap and
rarely act in isolation, and their effectiveness often
depends on the context in which they operate.
BACKGROUND
There is a widely held assumption that
engagement by clinicians and healthcare
organisations in research improves
healthcare performance at various levels,1 2
but little direct empirical evidence has previ-
ously been collated. A previous review (pub-
lished in 2011) looked at the effects on
patients of their healthcare practitioner’s or
organisation’s participation in clinical trials.3
It identified 13 papers and suggested that
the evidence to support a positive association
was less strong than previously thought.
Another paper, published in the same year,
reported that participants at an international
workshop held in 2009 had also concluded
that the literature on the impact of research
activity on the quality of healthcare outcomes
within research-active institutions and health-
care systems in general was not extensive.4
This current paper reports on a literature
review conducted to map and explore plaus-
ible mechanisms through which research
engagement might improve healthcare per-
formance at clinician or organisational level.
The review addressed the question, “Does
research engagement by clinicians and orga-
nisations improve healthcare performance?”,
and also sought to identify the mechanisms
that might be involved. Despite the obvious
Strengths and limitations of this study
▪ This review brings together for the first time a
diverse body of literature addressing whether
engaging clinicians and healthcare organisations
in research is the likely to improve healthcare
performance.
▪ It also explores the mechanisms through which
improvement is achieved to try and understand
how any improvements might come about.
▪ However, it relies on the quality and coverage of
the existing literature.
▪ It is an extremely complex topic, but nonetheless
one worthy of further exploration, particularly
given the pressure to justify research spending
in healthcare systems, and to encourage its
implementation.
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overlaps, this question is different from that of whether
individual patients benefit from trial participation on
which the 2009 workshop also commented, concluding
that on this second issue there was, in contrast, a ‘sub-
stantial literature’ but still, nonetheless, a lack of conclu-
sive evidence.4
Theoretical context
Numerous theoretical perspectives have a bearing on
our research question. For example, research engage-
ment has been conceptualised as a way of increasing the
ability and willingness of various groups of stakeholders
to use research. This includes the theory of absorptive
capacity, which seeks to explain how conducting
research and development (R&D) within an organisa-
tion can help that organisation develop and maintain its
broader capabilities to assimilate and exploit externally
available information from research.5 There is also litera-
ture focusing on the characteristics of individual
research adopters,6 7 and work on clinical leadership
and the role of medical academics.8
Other bodies of relevant theory seek to underpin
efforts to explore how better co-ordination of research
engagement might enhance the effectiveness of
research, including the development of research net-
works9 10 and initiatives designed to re-shape relations
between clinical research and healthcare delivery
systems such as the NIH Road Map in the USA,11 the
NIHR Collaborations for Leadership in Applied Health
Research and Care (CLAHRCs)12 and the Academic
Health Science Networks13 in the UK, and similar devel-
opments in other countries.14 15 Research engagement
has also been conceptualised as a way of ensuring that
research is used to improve the healthcare system,
drawing on theories of collaboration including the influ-
ential concept of ‘linkage and exchange’:16 Denis and
Lomas describe ‘four distinct, but clearly related aca-
demic traditions’ that converge on collaborative
research17 including: action research;18 participatory
research;19 programme evaluation; and knowledge-
utilisation research.
Finally, commentators have sought to explain how
research engagement at an organisational level can
improve the performance of healthcare organisations,
drawing on the theoretical approaches that have under-
pinned efforts to improve organisational performance in
healthcare and enhance the design and use of perform-
ance management systems. There are well-established lit-
eratures on promoting learning organisations, adopting
an organisational approach to quality improvement (QI)
and knowledge mobilisation.
However while these various literatures provide
insights into the review question and pointers to the
mechanisms through which research engagement might
improve outcomes, the component papers and the
reviews based on them do not, by and large, directly
consider the benefits of research engagement.
Furthermore, until recently research activity was not
generally included in the measures used to assess the
performance of healthcare organisations, the focus was
on measures of activity and cost.20
Scope of the review
Given this wide literature, the scope of the review was care-
fully considered. Its focus was on studies of practitioner or
organisational engagement in research, and the objective
was to explore the whole pathway from research engage-
ment to healthcare performance. With this in mind:
▸ ‘Engagement in research’ was taken to mean a delib-
erate set of intellectual and practical activities under-
taken by healthcare staff (including conducting
research and playing an active role in the whole
research cycle) and organisations (including playing
an active role in research networks, partnerships or
collaborations and ensuring the research function is
fully integrated into organisational structures). In
essence we therefore equated engagement in
research with participation in research throughout
the research cycle, and this understanding was
reflected in the search terms we used in the focused
review (see online additional file 1). We noted,
however, that the terms ‘engagement in research’ and
‘engagement with research’ are sometimes used inter-
changeably in the literature. At the start of our review
we therefore explored how far a broader definition of
research engagement could also include engagement
with research, taking this term to mean a less substan-
tial involvement at individual and team level related
to receiving and transmitting the findings of research.
This could include aspects of activities such as con-
tinuing medical education (CME), attempts to per-
suade clinicians to adopt guidelines, and knowledge
mobilisation more generally. However, such efforts
often focus on encouraging research utilisation
alone, and not on research utilisation as an integral
phase in the whole research cycle. Given the fact that
our brief was to explore the whole pathway from
research engagement to healthcare performance, we
finally decided to concentrate our resources on the
interpretation of research engagement as ‘engage-
ment in research’, in the sense given above. We also
decided that the scope of our review was already too
wide to include the slightly separate although equally
important topic of whether or not engaging the
public and patients as partners in research improved
healthcare performance.
▸ ‘Healthcare performance’ was understood to reflect
the consequences of clinical activity, and was primar-
ily taken to mean improvements in the processes and
outcomes of care, rather than other measures of
healthcare performance such as efficiency.
▸ ‘Mechanisms’ were seen in relatively simple terms as
levers that instigate and sustain activity, for example,
research collaborations between researchers and
healthcare staff who are potential users of the
findings.
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METHODS
An ‘hourglass’ review was undertaken that consisted of
three stages: (1) a broad mapping exercise exploring a
large number of bodies of literature that might contain
empirical evidence relating to the question and any
mechanisms and theoretical perspectives that might be
relevant; (2) a focused (or formal) review that concen-
trated on the core question of whether or not research
engagement improves healthcare; and (3) a wider (but
less systematic) review of papers identified during the two
earlier stages that were relevant to the review question,
and included many papers that did not meet the inclu-
sion criteria for the focused review. The hourglass shape
refers to the scope of the analysis at each stage, and to
the number of papers considered in detail; in terms of the
volume of titles and abstracts processed, the throughput
of the review was greatest in the second stage (figure 1).
A more detailed account of the review approach is avail-
able (see online additional file 2) The PRISMA checklist
for reporting systematic reviews was followed as far as was
feasible.21 Ethical approval was obtained from Brunel
University’s Research Ethics Committee.
Stage 1: Planning and mapping
The review team drew on their existing knowledge, initial
scans of potentially relevant literatures, team meetings
and brainstorming sessions, and on the knowledge and
experience of an advisory group of international experts
and patient representatives. The latter provided input
(largely by email) on the methods used in the review, the
literature identified and the findings emerging from the
synthesis. This mapping exercise explored the major the-
oretical approaches that could, potentially, inform the
conduct of the review and help to build a framework
within which to identify and analyse the mechanisms
through which engagement in research can improve
healthcare performance. It also informed the choice of
the search terms used in Stage 2.
Stage 2: Focused review
The search strategy involved a comprehensive search of
a wide range of relevant databases and sought to identify
empirical research studies (not limited to clinical trials)
—in which the concept of ‘engagement in research’ was
an input and some measure of healthcare ‘performance’
was an output (see figure 2; and see online additional
file 1). The search strategy covered the period 1990 to
March 2012. MEDLINE, EMBASE, PsycINFO,
Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Web of Science, Applied Social
Sciences Index and Abstracts (ASSIA), British Nursing
Index, Health Management Information Consortium
(HMIC) and System for Information on Grey Literature
in Europe (SIGLE) databases were searched. The data-
base searches were supplemented by manual searching
five journals that specialise in this area, by papers sug-
gested by the advisory group, and by snowballing.
English language terms were used for searching,
although papers identified through this route that were
not published in English were considered for inclusion.
The database searches identified 10 239 papers, and 159
were identified from other sources. The searches were
conducted by an information scientist, Sarah Jeal advised
by Sarah Lawson (a senior information scientist at King’s
College London), working closely with the review team.
The focused review involved an initial examination of
the title of each paper (and the abstract when neces-
sary) to exclude documents that were clearly not
Figure 1 The hourglass shaped
three-stage review.
Source: Hanney, Boaz, Jones,
Soper (2013).23
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relevant. Two or more reviewers then studied the titles
and full abstracts in greater depth to assess the eligibility
of each paper. Further relevance and quality checks on
473 papers were undertaken to determine whether or
not they were suitable to proceed to the data extraction
stage. We undertook an initial (broad) test for quality by
applying the Dixon-Woods ‘fatally flawed’ test.22 This
applies the following questions:
▸ Are the aims and objectives of the research clearly
stated?
▸ Is the research design clearly specified and appropri-
ate for the aims and objectives of the research?
▸ Do the researchers provide a clear account of the
process by which their findings were reproduced?
▸ Do the researchers display enough data to support
their interpretations and conclusions?
Figure 2 Flow diagram of the literature search for the focused review. Source: Hanney, Boaz, Jones, Soper (2013).23
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▸ Is the method of analysis appropriate and adequately
explicated?
The diversity of methods used in the papers meant
that no one quality appraisal tool could be rigidly
applied to all papers. The second quality check was,
therefore, method specific:
▸ For RCTs, controlled before and after studies and for
qualitative studies we used the relevant checklist pro-
vided by the Critical Appraisal Skills Programme (CASP
—see: http://www.casp-uk.net/#!checklists/cb36).
▸ For surveys we used the critical appraisal checklist devel-
oped by the Centre for Evidence-based Management
(see: http://www.cebma.org/wp-content/uploads/
Critical-Appraisal-Questions-for-a-Survey.pdf). This is an
approach adapted from a number of existing tools,
including: The Pocket Guide to Critical Appraisal
(BMJ Books 1996); the BMJ editor’s checklists
(http://www.bmj.com/about-bmj/resources-authors/
article-types/research/editors-checklists) and the
checklists of the Evidence for Policy and Practice
Information and Co-ordinating Centre (https://eppi.
ioe.ac.uk/cms).
The quality of the papers was considered as part of an
integrated assessment described as the ‘importance’
dimension discussed below. This was assessed through
the quality of the paper, the size of the study and rele-
vance to the focused review question.
Analysis
A heterogeneous mix of papers was identified and a
standard meta-analysis was not possible. This review
involved, therefore, an interpretive rather than an aggre-
gative synthesis.22 23 A data extraction sheet was com-
pleted for each paper and key aspects of the included
studies were collated in a table (table 1). To facilitate
analysis, a matrix was developed to characterise the cir-
cumstances in which research engagement might
improve healthcare performance and the mechanisms
that might be at work.
This matrix identified two dimensions: the degree of
intentionality and the scope of impact. Least intentional-
ity was when the improvement in healthcare perform-
ance resulting from engagement in research was a
by-product of research that was conducted with the
primary aim of testing a specific therapy or approach.
Greatest intentionality was when there was an explicit
intention to produce improvements in healthcare per-
formance as a direct consequence of research engage-
ment by healthcare staff through interventions such as
collaborations, participatory research and/or organisa-
tional approaches. Research networks were considered
to be in the middle of this spectrum.
Impact is generally defined as a ‘strong effect or influ-
ence’,24 and it was in this sense that the impact of
engagement in research was discussed in the focused
review papers—the majority of which sought evidence of
a positive association between research engagement and
improved healthcare outcomes or processes. Two
categories of the scope of impact were identified,
broader and specific. Broader impact referred to those
who had engaged in research being more willing and/
or able to provide evidence-based care that was based on
relevant research conducted anywhere, and that was not
related to the specific findings of the research in which
they were engaged. Specific impact referred to those
who had engaged in research being more willing and/
or able to provide evidence-based care that was related
to the specific findings of the research in which they
were engaged.
Each paper that reached the final data extraction step
was analysed using this matrix, and also in relation to:
▸ Importance of the paper to the review. This was
based on quality (including, where appropriate, how
well controlled the study was), size of the study and
relevance to the review question.
▸ Whether the findings of the paper were positive or
negative in relation to the review question (ie, positive
if they showed research engagement did improve
healthcare, and negative if not). Within each group
some were also classified as mixed.
▸ The level of engagement discussed (clinician or
organisational).
Stage 3: Wider review
The final stage was an informal wider review. This was
intended to support the findings of the focused review
and explore the mechanisms through which research
engagement might improve healthcare, building on
relevant theories. All the 440 papers excluded at the
full-paper review stage of the focused review were consid-
ered for this wider review, plus others identified during
the mapping stage and ongoing snowballing exercises.
Relevance was determined in relation to the theoretical
approaches outlined above and the review team’s emer-
ging understanding of the mechanisms involved.
RESULTS
Results of the focused review
Table 1 summarises the characteristics of the 33 papers
that were included in the focused review. The papers
covered 15 clinical fields, including 10 cancer research
papers and 6 cardiovascular studies. The papers came
from 9 countries, with nearly half (15) from the US and
another 5 from Canada.
Degree of intentionality: There were 21 by-product papers
(least intentionality), 8 network papers (mid-range
intentionality) and 4 intervention papers (greatest inten-
tionality). The focused review papers presented in
table 1 are organised according to this dimension.
Importance: Fourteen papers were identified as import-
ant and 19 less important in terms of their contribution
to the focused review question. The papers identified as
important are starred in table 1.
Level of engagement: The ratio of organisational to clin-
ician studies in the by-product and network categories
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Table 1 Findings from the focused review
Author(s) and details of paper Date
Clinical area
or procedure Country
Level of
study Impact Finding
Improvement
identified
By-product papers
Adler MW. Changes in local clinical practice following an experiment in
medical care: evaluation of evaluation. J Epidemiol Community Health
1978;32:143–6. http://dx.doi.org/10.1136/jech.32.2.143
1978 Inguinal hernia and
varicose veins
UK O S + P
Andersen M, Kragstrup J, Sondergaard J. How conducting a clinical trial
affects physicians’ guideline adherence and drug preferences. JAMA
2006;295:2759–64. http://dx.doi.org/10.1001/jama.295.23.2759*
2006 Asthma Denmark O S - P
Chen AY, Schrag N, Hao Y, Flanders WD, Kepner J, Stewart A, et al.
Changes in treatment of advanced laryngeal cancer 1985–2001.
Otolaryngol Head Neck Surg 2006;135:831–7. http://dx.doi.org/10.1016/j.
otohns.2006.07.012
2006 Cancer (laryngeal) US O B + P
Clark WF, Garg AX, Blake PG, Rock GA, Heidenheim AP, Sackett DL.
Effect of awareness of a randomized controlled trial on use of
experimental therapy. JAMA 2003;290:1351–5. http://dx.doi.org/10.1001/
jama.290.10.1351
2003 Apheresis Canada C S? M - P
Das D, Ishaq S, Harrison R, Kosuri K, Harper E, Decaestecker J, et al.
Management of Barrett’s esophagus in the UK: overtreated and
underbiopsied but improved by the introduction of a national randomised
trial. Am J Gastroenterol 2008;103:1079–89. http://dx.doi.org/10.1111/j.
1572-0241.2008.01790.x
2008 Barratt’s oesophagus UK C S + P
du Bois A, Rochon J, Lamparter C, PFisterer J, and for the
Organkommission OVAR. Pattern of care and impact of participation in
clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer
2005;15:183–91*
2005 Ovarian cancer Germany O B + HO
Hébert-Croteau N, Brisson J, Latreille J, Blanchette C, Deschenes
L. Variations in the treatment of early-stage breast cancer in Quebec
between 1988 and 1994. CMAJ 1999;161:951–5
1999 Breast cancer Canada O B + P
Janni W, Kiechle M, Sommer H, Rack B, Gauger K, Heinrigs M, et al.
Study participation improves treatment strategies and individual patient
care in participating centers. Anticancer Res 2006;26:3661–7. http://dx.
doi.org/10.1016/S0960-9776(05)80107-9
2006 Breast cancer Germany O S + P
Jha P, Deboer D, Sykora K, Naylor CD. Characteristics and mortality
outcomes of thrombolysis trial participants and nonparticipants: a
population-based comparison. J Am Coll Cardiol 1996;27:1335–42. http://
dx.doi.org/10.1016/0735-1097(96)00018-6
1996 AMI Canada O S M+ HO
Jones B, Ratzer E, Clark J, Zeren F, Haun W. Does peer-reviewed
publication change the habits of surgeons? Am J Surg 2000;180:566–9.
http://dx.doi.org/10.1016/S0002-9610(00)00495-5
2000 Appendectomy US C S - P
Karjalainen S, Palva I. Do treatment protocols improve end results? A
study of survival of patients with multiple myeloma in Finland. BMJ
1989;299:1069–72. http://dx.doi.org/10.1136/bmj.299.6707.1069
1989 Leucaemia Finland O S + HO
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Table 1 Continued
Author(s) and details of paper Date
Clinical area
or procedure Country
Level of
study Impact Finding
Improvement
identified
Kizer JR, Cannon CP, McCabe CH, Mueller HS, Schweiger MJ, Davis
VG, et al. Trends in the use of pharmacotherapies for acute myocardial
infarction among physicians who design and/or implement randomized
trials vs physicians in routine clinical practice: the MILIS-TIMI experience.
Multicenter investigation on limitation of infarct size. Am Heart J
1999;137:79–92
1999 AMI US C B + P
Majumdar SR, Chang W-C, Armstrong PW. Do the investigative sites that
take part in a positive clinical trial translate that evidence into practice?
Am J Med 2002;113:140–5. http://dx.doi.org/10.1016/S0002-9343(02)
01166-X*
2002 AMI Canada O S - P
Majumdar SR, Roe MT, Peterson ED, Chen AY, Gibler WB, Armstrong
PW. Better outcomes for patients treated at hospitals that participate in
clinical trials. Arch Intern Med 2008;168:657–62. http://dx.doi.org/10.
1001/archinternmed.2007.124*
2008 Unstable angina US O B + HO
Meineche-Schmidt V, Hvenegaard A, Juhl HH. Participation in a clinical
trial influences the future management of patients with
gastro-oesophageal reflux disease in general practice. Aliment Pharmacol
Ther 2006;24:1117–25. http://dx.doi.org/10.1111/j.1365-2036.2006.
03046.x*
2006 Gastro-oesophageal
reflux
Denmark C S + P
Morton AN, Bradshaw CS, Fairley CK. Changes in the diagnosis and
management of bacterial vaginosis following clinical research. Sex Health
2006;3:183–5. http://dx.doi.org/10.1071/SH06024
2006 Sexual health Australia C S M+ P
Pancorbo-Hidalgo PL, Garcia-Fernandez FP, Lopez-Medina IM,
Lopez-Ortega J. Pressure ulcer care in Spain: nurses’ knowledge and
clinical practice. J Adv Nurs 2007;58:327–38. http://dx.doi.org/10.1111/j.
1365-2648.2007.04236.x*
2006 Pressure ulcer Spain C B + P
Pons J, Sais C, Illa C, Méndez R, Suñen E, Casas M, et al. Is there an
association between the quality of hospitals’ research and their quality of
care? J Health Serv Res Policy 2010;15:204–9. http://dx.doi.org/10.1258/
jhsrp.2010.009125*
2010 AMI Spain O B + HO
Rich AL, Tata LJ, Free CM, Stanley RA, Peake MD, Baldwin DR, et al.
How do patient and hospital features influence outcomes in small-cell
lung cancer in England? Br J Cancer 2011;105:746–52. http://dx.doi.org/
10.1038/bjc.2011.310*
2011 Small cell lung cancer UK O B M+ P
Rochon J, du Bois A. Clinical research in epithelial ovarian cancer and
patients’ outcome. Ann Oncol 2011;22(Suppl. 7):vii16–19. http://dx.doi.
org/10.1093/annonc/mdr421*
2011 Ovarian cancer Germany O B + HO
Salbach NM, Guilcher SJ, Jaglal SB, Davis DA. Determinants of research
use in clinical decision making among physical therapists providing
services post-stroke: a cross-sectional study. Implementation Sci
2010;5:77. http://dx.doi.org/10.1186/1748-5908-5-77
2010 Stroke Canada C B + P
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Table 1 Continued
Author(s) and details of paper Date
Clinical area
or procedure Country
Level of
study Impact Finding
Improvement
identified
Network papers
Abraham AJ, Knudsen HK, Rothrauff TC, Roman PM. The adoption of
alcohol pharmacotherapies in the Clinical Trials Network: the influence of
research network participation. J Subst Abuse Treat 2010;38:275–83.
http://dx.doi.org/10.1016/j.jsat.2010.01.003*
2010 Alcohol-use disorders US O B + P
Carpenter WR, Reeder-Hayes K, Bainbridge J, Meyer A-M, Amos KD,
Weiner BJ, et al. The role of organizational affiliations and research
networks in the diffusion of breast cancer treatment innovation. Med Care
2011;49:172–9. http://dx.doi.org/10.1097/MLR.0b013e3182028ff2*
2011 Breast cancer US O B + P
Ducharme LJ, Knudsen HK, Roman PM, Johnson JA. Innovation
adoption in substance abuse treatment: exposure, trialability, and the
Clinical Trials Network. J Subst Abuse Treat 2007;32:321–9. http://dx.doi.
org/10.1016/j.jsat.2006.05.021*
2007 Substance abuse US O S M+ P
Knudsen HK, Abraham AJ, Johnson JA, Roman PM. Buprenorphine
adoption in the National Drug Abuse Treatment Clinical Trials Network. J
Subst Abuse Treat 2009;37:307–12. http://dx.doi.org/10.1016/j.jsat.2008.
12.004*
2009 Substance abuse US O S + P
Laliberte L, Fennell ML, Papandonatos G. The relationship of
membership in research networks to compliance with treatment
guidelines for early-stage breast cancer. Med Care 2005;43:471–9. http://
dx.doi.org/10.1097/01.mlr.0000160416.66188.f5*
2005 Breast cancer US O B + P
Rhyne R, Sussman AL, Fernald D, Weller N, Daniels E, Williams RL,
et al. Reports of persistent change in the clinical encounter following
research participation: a report from the Primary Care Multiethnic Network
(PRIME Net). J Am Board Fam Med 2011;24:496–502. http://dx.doi.org/
10.3122/jabfm.2011.05.100295
2011 Acanthosis Nigricans US C S + P
Siegel RM, Bien J, Lichtenstein P, Davis J, Khoury JC, Knight JE, et al. A
safety-net antibiotic prescription for otitis media: the effects of a PBRN
study on patients and practitioners. Clin Pediatr 2006;45:518–24. http://
dx.doi.org/10.1177/0009922806290567
2006 Otitis media US C S + P
Warnecke R, Johnson T, Kaluzny A, Ford L. The community clinical
oncology program: its effect on clinical practice. J Qual Improv
1995;21:336–9.
1995 Breast cancer US C S + P
Intervention papers
Chaney EF, Rubenstein LV, Liu C-F, Yano EM, Bolkan C, Lee M, et al.
Implementing collaborative care for depression treatment in primary care:
a cluster randomized evaluation of a quality improvement practice
redesign. Implement Sci 2011;6:121. http://dx.doi.org/10.1186/
1748-5908-6-121
2011 Depression US O S M+ P
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was approximately the same (13v8; 5v3). In contrast, all
the intervention studies were at the organisational level.
In total, 22 papers were at the organisational level, of
which 19 were positive; and 11 at the clinician level, of
which 9 were positive.
Positive papers: A majority of the papers (28) were posi-
tive with regard to whether research engagement
improved healthcare performance. However, only a
minority of the positive cases (7 out of 28) reported
improved health outcomes, the remainder reported
improved (usually more evidence-based) processes of
care. Among the papers reporting improved health out-
comes, two German studies explored the association
between hospital trial participation and processes and
outcomes such as the use of guideline-indicated care
and in-hospital mortality for patients with ovarian
cancer. These studies found that overall survival was sig-
nificantly worse in patients treated in non-study hospi-
tals.25 26 Similarly, patients treated for unstable angina in
US hospitals participating in clinical trials were found to
have significantly lower mortality than those treated in
non-participating hospitals,27 and a Spanish study of the
relationship between bibliometric measures of research
output in acute hospitals and hospital mortality for two
common cardiac conditions found a low-to-moderate
negative correlation between the risk-adjusted mortality
ratio and the weighted citations ratio.28
Among the papers reporting improvements in the pro-
cesses of care, a UK study of patients with small-cell lung
cancer concluded that patients first seen at a hospital
with a keen interest in clinical trials are more likely to
receive chemotherapy,29 and two US studies of patients
treated for breast cancer at facilities that were members
of cancer research networks found that they were more
likely to receive guideline-concordant treatment or be
given innovative treatment offering promise.30 31 This
latter finding about the positive influence of involve-
ment in research networks on organisational innovation
was also confirmed in three US studies on alcohol and
substance abuse.32–34
Impact: Taken together, the papers were divided almost
equally into those with a broader impact on healthcare
performance (16) and those with a more specific impact
(17) (although all the intervention studies described a
specific impact). Within this overall balance, 13 of the
28 positive studies described a broader impact and these
included 10 out of the 17 positive by-product studies.
Results of the wider review
More than 80 papers included in the wider review
reported on studies that illustrated some progress along
the pathway from research engagement to improved
healthcare (but that had not gone far enough to be
included in the focused review). The wider review pro-
vided further evidence to support the findings of the
focused review about the nature of the relationship
between research engagement and healthcare outcomes,
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the mechanisms involved and the role of the context
provided by health organisations and systems.
DISCUSSION
Overall on the basis of the analysis of the papers in the
focused review, it is reasonable to suggest that when clin-
icians and healthcare organisations engage in research
there is the likelihood of improvement in their health-
care performance, even when that has not been the
primary aim of the research. This evidence related
mainly, though not exclusively, to improvement in the
processes of care rather than in health outcomes.
What these findings indicate about the mechanisms
involved
The 21 ‘by-product’ papers with the degree of least
intentionality constituted the largest group in the
focused review (see table 2). In these papers the main
purpose of the original research engagement (by clini-
cians or organisations) was to conduct or participate in
research studies to evaluate new therapies, procedures,
etc. The by-product papers were separate studies, usually
conducted later, that explored the impact on healthcare
that had arisen as ‘by-products’ of the research engage-
ment in the original study and sometimes analysed, or
speculated about, what might have caused this impact.
In the sense used in this review, the term ‘by product’ is
therefore in some circumstances associated with the
concept of ‘absorptive capacity’. There were 17 positive
‘by-product’ papers, 10 reporting a broad impact (the
use of research findings from wherever they come) and
7 reporting a more specific impact (use of research find-
ings from a specific study in which the research engage-
ment occurs). The discussions in these papers suggest
that at clinician and organisational levels different
mechanisms—such as changes in clinicians’ attitudes
and behaviour or the long-term use of infrastructure
created to support a particular trial—may be at play (see
table 2).
The second largest group of papers in the focused
review was the eight network papers, which described
the situation broadly in the middle of the spectrum of
intentionality. All these papers came from the US,
reflecting the more established nature of formal
research networks in the USA, and also an approach to
evaluation that is consistent with the inclusion criteria
used for the focused review. All the network papers were
positive, and the mechanisms discussed by the authors
represent a partial formalisation and use on a regular
basis (through the provision of more effective collabor-
ation and more supportive contexts) of those mechan-
isms discussed in the by-product papers (see table 2).
The partial formalisation and the importance of
context identified in the network papers were taken still
further in interventions deliberately designed to inte-
grate the research function into organisational struc-
tures. These were described in the four intervention
papers in the focused review,35–38 and included collab-
orative approaches, quality improvement research initia-
tives, participatory and action research, and
organisational approaches where the intention was expli-
citly to produce improvements in healthcare perform-
ance as a direct consequence of the research
engagement of the organisation. One of these studies
was positive,37 two were mixed/positive35 38 and one was
categorised as mixed/negative36 because the improve-
ments that were achieved during the intervention
project were later reversed. Most of the improvements
described were in healthcare processes, although
improvements in health outcomes were reported in one
study.38 These four intervention papers largely described
the adoption of the specific research that featured in
the intervention. However, they also raised issues about
how broader impact can be achieved throughout an
organisation which resonate with how research networks
operate, such as the importance of effective collabor-
ation (see table 2).
The formalisation of engagement by clinicians and
healthcare organisations in research
The largest group of the papers categorised as import-
ant in the focused review were those in which the level
of engagement considered was organisational and the
scope of impact discussed was broad. This finding ties in
with the increasing formalisation of attempts to promote
what were hitherto often viewed as the ‘by-product’ ben-
efits of research engagement. This formalisation is
exemplified in recent initiatives designed to promote
clinical research and to encourage the translation of
research such as the development of research networks,
the NIH Road Map in the USA,11 the NIHR
Collaborations for Leadership in Applied Health
Research and Care in the UK.12 In an important realign-
ment of objectives, these moves towards trials and other
well-found research taking place within networks and as
part of wider interventions mean that increasingly
research engagement leading to improved healthcare
performance is shifting from being a by-product to an
intended outcome of research funding. To date the
effect of institutional research activity on patient out-
comes and, specifically, the organisational factors that
can facilitate or hinder provider participation in
research and that underpin implementation effective-
ness have not been investigated extensively.39 40
However, there was evidence from the wider review that
initiatives such as those described above are beginning
to result in progress being made along the pathway from
research engagement to improved healthcare.41 And
this evidence has since been supplemented by more
recently published papers that report that research
active UK NHS Trusts have lower risk-adjusted mortality
for acute admissions42 43 (a conclusion that supports the
Spanish-based findings of the earlier focused-review
paper by Pons et al28), and that describe the positive out-
comes being achieved by initiatives such as the UK
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Table 2 Mechanisms through which research engagement may improve healthcare performance
Mechanisms identified in the focused review Insights from the wider review
By product papers
Broad impact Specific impact ▸ Research-active staff may differ from their peers
in non-research-active settings because of:
personal characteristics, multidisciplinary
collaboration, additional training and education
or specialisation
▸ An increasing recognition of the ‘by-product’
type benefits from research engagement has
encouraged further thinking about how best to
build on and regularise these opportunities
Clinician ▸ Change in attitudes and behaviour that
research engagement can promote
▸ Involvement in the processes of research
▸ Greater awareness and understanding of
the specific research findings
Organisation ▸ Use of the infrastructure created to support
trials more widely, or for a longer period, to
improve patient care
▸ Applying the processes and protocols
developed in a specific study (not counting
any impact from regimens in the
intervention arm) to all patients with specific
illness, irrespective of their involvement in
the trialNetwork papers
Clinician ▸ Increased relevance of the research
▸ Increased knowledge and understanding of
the findings gained through participation in
the research
▸ Clinician participation in research networks
particularly effective when the science is
changing rapidly and when keeping
up-to-date is critical
▸ Mechanisms such as practice facilitators,
project development meetings and network
convocations allow two-way knowledge
exchange throughout a research network,
enabling clinicians to engage with question
generation and the resulting research, and
ensuring that the research is more relevant to
practitioners
▸ Limitations about what can be achieved by
research networks
▸ Need for a supportive context that enables
clinicians and their organisations to participate
in research and research networks
▸ Evidence of a growing international interest in
the benefits that might come from research
networks
Organsational ▸ Centres within networks build up a record of
implementing research findings
▸ Network membership increases the likelihood
of physicians recommending guideline
concordant treatment
▸ Organisations affiliated to a network adopt an
integrated, programmatic approach to
improving the quality of care, including the
professional education, training and national
meetings provided
Intervention papers
Organisation ▸ The importance of effective collaboration
and the need for a supportive context
▸ Healthcare organisations and systems provide
the context within which research engagement
operates at other levels
▸ Organisations in which the research function is
fully integrated into the organisational structure
can out-perform other organisations that pay
less heed to research and its outputs
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NIHR CLAHRCs44 45 and the US NIH’s Clinical and
Translational Science Awards.46
The nature of the relationship between research
engagement and healthcare improvement
Throughout this review the term ‘impact’ was used to
mean the influence or effect that research engagement
might have on healthcare improvement. The nature of
this relationship was discussed in some (though not all)
of the papers in the focused review whose authors iden-
tified various measures of research activity (such as
recruitment to trials27 or production of peer-reviewed
papers28 or affiliation to a research network30 32), high-
lighted confounding factors (such as hospital teaching
status28), and undertook multivariate analysis to establish
the nature and strength of any association.30 32
Overall, it is clear that at both clinician and organisa-
tional levels engagement in research differs in intensity
and in form, operates through a variety of mechanisms,
and is only one of many influences on performance.
Although for the reasons given above, the literature on
‘engagement with research’ did not fall within the inclu-
sion criteria for this review, this literature is considerably
more established than the literature on ‘engagement in
research’, and has interesting parallels with the conclu-
sions of our own review. In particular, both literatures
recognise that there is no single magic bullet47 and that
there is a need for multiple parallel strategies to encour-
age engagement both with and in research in order to
improve healthcare performance.48
Evaluating the effect of active engagement in research of
the sort identified in this review is, therefore, not ‘a trivial
issue’.26 For example, at organisational level one measure
of research engagement is the extent of patient enrolment
in trials. However, healthcare organisations that participate
actively in trials may have other institutional characteristics
that also improve patient outcomes, such as a high volume
of patients, well-respected training programmes and well-
motivated, highly educated staff; and there is considerable
potential for confounding.27 In order to establish an asso-
ciation between research engagement and improvement
in healthcare, it is, therefore, necessary for studies to
adjust for such institutional characteristics,4 and for other
attributes such as organisational culture.41 Having estab-
lished an association, further data on whether this effect
increases with higher levels of participation27 and over the
time an institution is research-active are needed to provide
evidence of causation.
Disaggregating how the various mechanisms through
which research engagement improves performance
operate in complex healthcare systems and factoring the
role of ‘organisational form’ into all this41 is also not
straightforward.40 49–51 Both the focused and the wider
reviews identified situations in which impacts seemed
less likely to arise from research engagement, and in
which the operation of networks and schemes aimed at
involving clinicians more fully in research faced difficul-
ties in making progress, particularly when there were
not changes at the organisational level to support these
initiatives.36 52 This suggests that, if we are to understand
better why “…healthcare institutions or service providers
who are active in research deliver better care and out-
comes than those who do not participate in clinical
research?”,4 more work is needed to encourage engage-
ment both in and with research in order to identify the
organisational determinants of implementation effective-
ness and thereby improve healthcare performance. This
might, for example, mean building on the work under-
taken by Teal et al41 in which they used an organisational
model of innovation implementation that identified six
factors that facilitate or hinder implementation: an orga-
nisation’s readiness for change, the level of management
support and resources available, the implementation
policies and practices that the organisation puts into
place, the climate for implementation that results from
these policies and practices, and the extent to which
intended users of the innovation perceive that innov-
ation use fosters the fulfilment of their values. Or
exploring further the insights developed by the US
Veterans Health Administration that suggest that having
researchers nested in a fully integrated healthcare deliv-
ery system with a stable patient population that has an
exceptionally high prevalence of chronic conditions pro-
vides them ‘with unparalleled opportunities to translate
research questions into studies and research findings
into clinical action’.53 A different but equally promising
approach is the use of a form of statistical analysis—
mediation analysis—to assess the mediating effect of
various clinical pathways on the impact of research activ-
ity on patient outcomes.40
Limitations
Many bodies of literature address the broad question of
whether research engagement improves performance,
but most published papers do so tangentially. The initial
mapping stage therefore sought to identify papers pub-
lished in different fields, journals and countries, and a
significant amount of time had to be dedicated to this
and to refining the question and developing search
terms. The focused review shared the limitations of
other systematic reviews in that it inevitably excluded
large volumes of potentially interesting, relevant
research that did not meet the inclusion criteria or that
provided too little information about key elements of
the study (such as design and outcomes). In particular,
studies assessing the impact made on clinician behaviour
by small, locally conducted pieces of research were diffi-
cult to interpret without full knowledge of the context.
A wider additional synthesis (the wider review) was
undertaken to support the findings of the focused
review and give the final review more explanatory power.
Another common limitation in systematic reviews is the
reliance of reviewers on what is already published in the
literature, and one result of this was that the section of
the focused review on networks drew exclusively on US
studies of research networks. Linked to this is another
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challenge common to systematic reviews: the impact of
publication bias and, specifically, towards the publication
of studies with positive results. This was addressed by
searching the grey literature, conducting a web search
and writing to some key authors in the field to identify
unpublished literature.
CONCLUSION
Systematic analysis of the data related to the engagement
by clinicians and healthcare organisations in research is
in its infancy, despite widely held assumptions about the
benefits of this engagement. The focused review reported
above concluded that there is some positive evidence
(albeit limited) that engagement by clinicians and
healthcare organisations in research can improve health-
care performance. However, although the focused review
also identified a range of mechanisms through which
engagement by clinicians and healthcare organisations in
research might result in improved healthcare perform-
ance, and the wider review added additional evidence, it
remains unclear how these effects are produced.
Overall what was clear, however, is that there are many
circumstances and mechanisms at work, more than one
mechanism is often operative and the evidence available
for each one is limited. These mechanisms overlap and
rarely act in isolation, and their effectiveness depends
on the context in which they operate. The number of
research networks is growing, and the contribution of
collaborative approaches to research is also developing.
At an organisational level there is an increasing formal-
isation of potential mechanisms, and research processes
themselves have become an important means through
which research engagement can improve healthcare per-
formance. Allied to these developments there is a need
for further empirical research, including more fine-
grained organisational studies that consider not only the
research engagement of all the relevant actors but also
the organisational determinants of implementation
effectiveness.
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